You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

Elacestrant dihydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for elacestrant dihydrochloride and what is the scope of patent protection?

Elacestrant dihydrochloride is the generic ingredient in one branded drug marketed by Stemline Therap and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Elacestrant dihydrochloride has one hundred and sixteen patent family members in twenty-six countries.

One supplier is listed for this compound.

Summary for elacestrant dihydrochloride
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for elacestrant dihydrochloride
Generic Entry Date for elacestrant dihydrochloride*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for elacestrant dihydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
QuantumLeap Healthcare CollaborativePhase 2
Carrick Therapeutics LimitedPhase 1/Phase 2
Berlin-Chemie AG Menarini GroupPhase 1/Phase 2

See all elacestrant dihydrochloride clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for elacestrant dihydrochloride

US Patents and Regulatory Information for elacestrant dihydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Stemline Therap ORSERDU elacestrant dihydrochloride TABLET;ORAL 217639-002 Jan 27, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Stemline Therap ORSERDU elacestrant dihydrochloride TABLET;ORAL 217639-002 Jan 27, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Stemline Therap ORSERDU elacestrant dihydrochloride TABLET;ORAL 217639-002 Jan 27, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Stemline Therap ORSERDU elacestrant dihydrochloride TABLET;ORAL 217639-002 Jan 27, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for elacestrant dihydrochloride

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3122426 CA 2024 00007 Denmark ⤷  Sign Up PRODUCT NAME: ELACESTRANT OR A SALT THEREOF; REG. NO/DATE: EU/1/23/1757 20230918
3122426 3/2024 Austria ⤷  Sign Up PRODUCT NAME: ELACESTRANT ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/23/1757 (MITTEILUNG) 20230918
3122426 PA2024504 Lithuania ⤷  Sign Up PRODUCT NAME: ELACESTRANTAS ARBA JO DRUSKA; REGISTRATION NO/DATE: EU/1/23/1757 20230915
3122426 301263 Netherlands ⤷  Sign Up PRODUCT NAME: ELACESTRANT, DESGEWENST IN DE VORM VAN ELACESTRANTDIHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/23/1757 20230918
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.